INMB insider transaction filings
Inmune Bio, Inc. — 17 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-07. Screen INMB transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-07 | 4 | Juda Scott — Director | Option exercise (M): 14,801 @ $1.40 · Option exercise/expiry (X): 14,801 (derivative) @ $0.12 | EDGAR |
| 2026-07-07 | 4 | Lowdell Mark William — Chief Scientific Officer | Option exercise (M): 7,211 @ $1.40 · Option exercise/expiry (X): 7,211 (derivative) @ $0.12 | EDGAR |
| 2026-07-07 | 4 | Moss David J — Chief Executive Officer, Director | Option exercise (M): 9,014 @ $1.40 · Option exercise/expiry (X): 9,014 (derivative) @ $0.12 | EDGAR |
| 2025-12-02 | 4 | Lowdell Mark William — Chief Scientific Officer | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2025-12-02 | 4 | Ellspermann Cory Randall — CFO | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2025-12-02 | 4 | Schroeder Timothy j — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-02 | 4 | Juda Scott — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-02 | 4 | Ganjei James Kelly — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-12-02 | 4 | Moss David J — Chief Executive Officer, Director | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2025-12-02 | 4 | ALLEN MARCIA — Director | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-11-18 | 4 | Schroeder Timothy j — Director | Disposition to issuer (D): 108,000 (derivative) · Grant/award (A): 108,000 (derivative) · Disposition to issuer (D): 108,000 (derivative) · Grant/award (A): 108,000 (derivative) · Disposition to issuer (D): 15,975 (derivative) · Grant/award (A): 15,975 (derivative) · +10 more | EDGAR |
| 2025-11-18 | 4 | Lowdell Mark William — Chief Scientific Officer | Disposition to issuer (D): 400,000 (derivative) · Grant/award (A): 400,000 (derivative) · Disposition to issuer (D): 180,000 (derivative) · Grant/award (A): 180,000 (derivative) · Disposition to issuer (D): 104,000 (derivative) · Grant/award (A): 104,000 (derivative) · +4 more | EDGAR |
| 2025-11-18 | 4 | Juda Scott — Director | Disposition to issuer (D): 108,000 (derivative) · Grant/award (A): 108,000 (derivative) · Disposition to issuer (D): 108,000 (derivative) · Grant/award (A): 108,000 (derivative) · Disposition to issuer (D): 15,975 (derivative) · Grant/award (A): 15,975 (derivative) · +10 more | EDGAR |
| 2025-11-18 | 4 | Ganjei James Kelly — Director | Disposition to issuer (D): 108,000 (derivative) · Grant/award (A): 108,000 (derivative) · Disposition to issuer (D): 108,000 (derivative) · Grant/award (A): 108,000 (derivative) · Disposition to issuer (D): 15,975 (derivative) · Grant/award (A): 15,975 (derivative) · +10 more | EDGAR |
| 2025-11-18 | 4 | Ellspermann Cory Randall — Interim CFO | Disposition to issuer (D): 75,000 (derivative) · Grant/award (A): 75,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) · Grant/award (A): 40,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Grant/award (A): 30,000 (derivative) · +4 more | EDGAR |
| 2025-11-18 | 4 | Moss David J — Chief Executive Officer, Director | Disposition to issuer (D): 400,000 (derivative) · Grant/award (A): 400,000 (derivative) · Disposition to issuer (D): 59,337 (derivative) · Grant/award (A): 59,337 (derivative) · Disposition to issuer (D): 275,000 (derivative) · Grant/award (A): 275,000 (derivative) · +10 more | EDGAR |
| 2025-11-18 | 4 | ALLEN MARCIA — Director | Disposition to issuer (D): 108,000 (derivative) · Grant/award (A): 108,000 (derivative) · Disposition to issuer (D): 15,975 (derivative) · Grant/award (A): 15,975 (derivative) · Disposition to issuer (D): 19,025 (derivative) · Grant/award (A): 19,025 (derivative) · +8 more | EDGAR |
Recent 8-K events — Inmune Bio, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-31 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-23 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-02 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-23 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-19 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=INMB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →